Beyond the cholinergic hypothesis: Do current drugs work in alzheimer's disease?

CNS Neuroscience and Therapeutics

Volumn 16, Issue 4, 2010, Pages 235-245

  Martorana, Alessandro ^a,b   Esposito, Zaira ^a   Koch, Giacomo ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Acetylcholine; Alzheimer's disease; Amines; Circadian rhythm; Nicotinic receptor

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOOTROPIC AGENT; NORADRENALIN; RIVASTIGMINE; SEROTONIN; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CIRCADIAN RHYTHM; COGNITIVE DEFECT; DRUG EFFICACY; HUMAN; LEARNING; MEMORY; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; OUTCOME ASSESSMENT; REVIEW; SENILE PLAQUE; ANIMAL; BIOLOGICAL MODEL; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; GENETICS; METABOLISM;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; CIRCADIAN RHYTHM; COGNITION DISORDERS; HUMANS; MODELS, BIOLOGICAL;

EID: 77954369899     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00175.x     Document Type: Review

References (117)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002 297 : 353 356.
2. Bartus RT, Dean RL III., Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982 217 : 408 414.
3. Parsons CG, Stöffler A, Danysz W. Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007 53 : 699 723.
4. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med 2010 12 : 13 26.
5. Geldmacher DS. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Practical considerations for the primary care physician. Prim Care Companion J Clin Psychiatry 2003 5 : 251 259.
6. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006 10 : 417 429.
7. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004 12 : 358 369.
8. Forchetti CM. Treating patients with moderate to severe Alzheimer's disease: Implications of recent pharmacologic studies. Prim Care Companion J Clin Psychiatry 2005 7 : 155 161.
9. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006 CD005593.
10. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006 10 : iii-iv, ix-xi, 1 160.
11. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Prim Care Companion J Clin Psychiatry 2006 8 : 158 159.
12. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006 21 : 17 28.
13. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008 148 : 379 397.
14. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis. Drugs Aging 2007 24 : 155 167.
15. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. Clin Interv Aging 2008 3 : 211 225.
16. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009 1 : 1 7.
17. Robles A. Pharmacological treatment of Alzheimer's disease: Is it progressing adequately? Open Neurol J 2009 3 : 27 44
18. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev 2000 CD001190.
19. Zhu XD, Giacobini E. Second generation cholinesterase inhibitors: Effect of (L)-huperzine-A on cortical biogenic amines. J Neurosci Res 1995 41 : 828 835.
20. Trabace L, Coluccia A, Gaetani S, et al. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res 2000 865 : 268 271.
21. Giacobini E, Zhu XD, Williams E, Sherman KA. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996 35 : 205 211.
22. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005 26 : 104 111.
23. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009 6 : 86 96.
24. Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease. CNS Drugs 2007 21 : 177 184.
25. Schredl M, Weber B, Leins ML, Heuser I. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. Exp Gerontol 2001 36 : 353 361.
26. Hornung OP, Regen F, Danker-Hopfe H, Schredl M, Heuser I. The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication. Biol Psychiatry 2007 61 : 750 757.
27. Blokland A. Acetylcholine: A neurotransmitter for learning and memory? Brain Res Brain Res Rev 1995 21 : 285 300.
28. Wisman LA, Sahin G, Maingay M, Leanza G, Kirik D. Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. J Neurosci 2008 28 : 7797 7807.
29. Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: A parallel neurochemical and behavioural analysis. J Neurochem 2007 100 : 1047 1061. (Pubitemid 46213928)
30. Brooks DJ. Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. Wien Klin Wochenschr 2006 118 : 570 572.
31. Cassel JC, Jeltsch H, Neufang B, Lauth D, Szabo B, Jackisch R. Downregulation of muscarinic- and 5-HT1B-mediated modulation of [3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin. Brain Res 1995 704 : 153 166.
32. Clarke PB, Reuben M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: Mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. Br J Pharmacol 1996 117 : 595 606.
33. Kenny PJ, File SE, Neal MJ. Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem 2000 75 : 2409 2414.
34. Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 2002 80 : 1071 1078.
35. Woolley ML, Marsden CA, Sleight AJ, Fone KC. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology 2003 170 : 358 367.
36. Barik J, Wonnacott S. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: Interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol Pharmacol 2006 69 : 618 628.
37. Rousseau SJ, Jones IW, Pullar IA, Wonnacott S. Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H]d-aspartate release from rat frontal cortex in vitro. Neuropharmacology 2005 49 : 59 72.
38. Ikonomovic MD, Wecker L, Abrahamson EE, et al. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Arch Neurol 2009 66 : 646 651.
39. Bencherif M, Lippiello PM. Alpha7 neuronal nicotinic receptors: The missing link to understanding Alzheimer's etiopathology? Med Hypotheses 2010 74 : 281 285.
40. Counts SE, He B, Che S, Ikonomovic MD, DeKosky ST, Ginsberg SD, Mufson EJ. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol 2007 64 : 1771 1776.
41. Galindo-Charles L, Hernandez-Lopez S, Galarraga E, et al. Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholin receptors. Synapse 2008 62 : 601 615.
42. Fone KC. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 2008 55 : 1015 1022.
43. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005 43 : 442 449.
44. Smith GS, Kramer E, Ma Y, Hermann CR, Dhawan V, Chaly T, Eidelberg D. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain 2009 132 : 392 401.
45. Martorana A, Stefani A, Palmieri MG, Esposito Z, Bernardi G, Sancesario G, Pierantozzi M. L-dopa modulates motor cortex excitability in Alzheimer's disease patients. J Neural Transm 2008 115 : 1313 1319.
46. Martorana A, Mori F, Esposito Z, et al. Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients. Neuropsychopharmacology 2009 34 : 2323 2328.
47. Preda S, Govoni S, Lanni C, Racchi M, Mura E, Grilli M, Marchi M. Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 2008 33 : 1062 1070.
48. Reid RT, Sabbagh MN. Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. J Alzheimers Dis 2003 5 : 429 436.
49. Reid RT, Sabbagh MN. Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro? J Neural Transm 2008 115 : 1437 1444.
50. Kenney JW, Gould TJ. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 2008 38 : 101 121.
51. Placzek AN, Zhang TA, Dani JA. Nicotinic mechanisms influencing synaptic plasticity in the hippocampus. Acta Pharmacol Sin 2009 30 : 752 760.
52. Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 2004 66 : 538 544.
53. Sharp BM, Yatsula M, Fu Y. Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther 2004 309 : 1116 1123.
54. Shearman E, Rossi S, Szasz B, et al. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study. Brain Res Bull 2006 69 : 204 213.
55. Schilström B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007 32 : 43 53.
56. Berlanga ML, Simpson TK, Alcantara AA. Dopamine D5 receptor localization on cholinergic neurons of the rat forebrain and diencephalon: A potential neuroanatomical substrate involved in mediating dopaminergic influences on acetylcholine release. J Comp Neurol 2005 492 : 34 49.
57. Kumar U, Patel SC. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res 2007 1131 : 187 196.
58. Power AE. Slow-wave sleep, acetylcholine, and memory consolidation. Proc Natl Acad Sci USA 2004 101 : 1795 1796.
59. Gais S, Born J. Declarative memory consolidation: Mechanisms acting during human sleep. Learn Member 2004 11 : 679 685.
60. Rasch BH, Born J, Gais S. Combined blockade of cholinergic receptors shifts the brain from stimulus encoding to memory consolidation. J Cogn Neurosci 2006 18 : 793 802.
61. Saint-Mleux B, Eggermann E, Bisetti A, et al. Nicotinic enhancement of the noradrenergic inhibition of sleep-promoting neurons in the ventrolateral preoptic area. J Neurosci 2004 24 : 63 67.
62. Hatton GI, Yang QZ. Synaptic potentials mediated by alpha 7 nicotinic acetylcholine receptors in supraoptic nucleus. J Neurosci 2002 22 : 29 37.
63. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: Modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003 42 : 33 84.
64. Berridge CW. Noradrenergic modulation of arousal. Brain Res Rev 2008 58 : 1 17.
65. Deschennes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep 2009 11 : 20 26.
66. Stopa EG, Volicer L, Kuo-Leblanc V, Harper D, Lathi D, Tate B, Satlin A. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 1999 58 : 29 39.
67. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 2008 5 : 342 345.
68. Moraes Wdos S, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: A double-blind placebo-controlled study. Sleep 2006 29 : 199 205.
69. Cooke JR, Loredo JS, Liu L, et al. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs Aging 2006 23 : 503 511.
70. Mizuno S, Kameda A, Inagaki T, Horiguchi J. Effects of donepezil on Alzheimer's disease: The relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin Neurosci 2004 58 : 660 665.
71. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dement Geriatr Cogn Disord 1999 10 : 237 244.
72. Rogers SL. Perspectives in the management of Alzheimer's disease: Clinical profile of donepezil. Dement Geriatr Cogn Disord 1998 9 (Suppl 3 29 42.
73. Davis B, Sadik K. Circadian cholinergic rhythms: Implications for cholinesterase inhibitor therapy. Dement Geriatr Cogn Disord 2006 21 : 120 129.
74. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010 64 : 651 660.
75. Nieoullon A, Bentué-Ferrer D, Bordet R, Tsolaki M, Förstl H. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: Focus on galantamine. Curr Med Res Opin 2008 24 : 3357 3367.
76. Giacobini E. Cholinesterases: New roles in brain function and in Alzheimer's disease. Neurochem Res 2003 28 : 515 522.
77. Shimohama S, Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psychiatry 2001 49 : 233 239.
78. Zeng H, Zhang Y, Peng L, et al. Nicotine and amyloid formation. Biol Psychiatry 2001 49 : 248 257.
79. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996 35 : 13568 13578.
80. Hellström-Lindahl E, Court J, Keverne J, et al. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 2004 19 : 2703 2710.
81. Nordberg A, Hellström-Lindahl E, Lee M, et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002 81 : 655 658.
82. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006 51 : 474 486.
83. Takada-Takatori Y, Kume T, Izumi Y, et al. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 2009 32 : 318 324.
84. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001 21 : 4125 4133.
85. Dineley KT, Xia X, Bui D, Sweatt JD, Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002 277 : 22768 22780.
86. Martin SE, de Fiebre NE, de Fiebre CM. The alpha7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against beta-amyloid1-42 toxicity in primary neuron-enriched cultures. Brain Res 2004 1022 : 254 256.
87. Mousavi M, Hellström-Lindahl E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem Int 2009 54 : 237 244.
88. Gay EA, Giniatullin R, Skorinkin A, Yakel JL. Aromatic residues at position 55 of rat alpha7 nicotinic acetylcholine receptors are critical for maintaining rapid desensitization. J Physiol 2008 586 : 1105 1115.
89. Barthet G, Framery B, Gaven F, et al. 5-Hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 2007 18 : 1979 1991.
90. Mlinar B, Mascalchi S, Morini R, Giachi F, Corradetti R. MDMA induces EPSP-Spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors. Neuropsychopharmacology 2008 33 : 1464 1475.
91. Perez-Garcia G, Meneses A. Memory formation, amnesia, improved memory and reversed amnesia: 5-HT role. Behav Brain Res 2008 195 : 17 29.
92. Maillet M, Robert SJ, Lezoualc'h F. New insights into serotonin 5-HT4 receptors: A novel therapeutic target for Alzheimer's disease? Curr Alzheimer Res 2004 1 : 79 85.
93. Cho S, Hu Y. Activation of 5-HT4 receptors inhibits secretion of beta-amyloid Peptides and increases neuronal survival. Exp Neurol 2007 203 : 274 278.
94. Cachard-Chastel M, Lezoualc'h F, Dewachter I, et al. 5-HT4 receptor agonists increase sAPP alpha levels in the cortex and hippocampus of male C57BL/6j mice. Br J Pharmacol 2007 150 : 883 892.
95. Russo O, Berthouze M, Giner M, et al. Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. J Med Chem 2007 50 : 4482 4492.
96. Cachard-Chastel M, Devers S, Sicsic S, Langlois M, Lezoualc'h F, Gardier AM, Belzung C. Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behav Brain Res 2008 187 : 455 461.
97. Warpman U, Alafuzoff I, Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain - Alterations in Alzheimer's disease. Neurosci Lett 1993 150 : 39 43.
98. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia. J Neurosci Res 1992 31 : 103 111.
99. Müller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 1997 60 : 985 991.
100. DeLapp N, Wu S, Belagaje R, et al. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells. Biochem Biophys Res Commun 1998 244 : 156 160.
101. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006 49 : 671 682.
102. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008 117 : 232 243.
103. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC. Signal transduction during amyloid-beta-peptide neurotoxicity: Role in Alzheimer disease. Brain Res Brain Res Rev 2004 47 : 275 289.
104. Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czerniawski JL, Aliev G. Am integrated treatment approach improves cognitive function in demented and clinically depressed patients. J Alzheimers Dis Other Demen 2005 20 : 21 26.
105. Rozzini L, Chilovi BV, Conti M, Bertoletti E, Zanetti M, Trabucchi M, Padovani A. Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. Int Psychogeriatr 2010 22 : 114 119.
106. Di Lazzaro V, Oliviero A, Tonali PA, et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 2002 13 : 392 397.
107. Di Lazzaro V, Oliviero A, Pilato F, et al. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psych 2004 75 : 555 559. (Pubitemid 38406651)
108. Pierantozzi M, Panella M, Palmieri MG, et al. Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia. Clin Neurophysiol 2004 115 : 2410 2418.
109. Kirvell SL, Esiri M, Francis PT. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 2006 98 : 939 950.
110. Kashani A, Lepicard E, Poirel O, et al. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 2008 29 : 1619 1630.
111. Lipton SA. Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007 8 : 621 632.
112. Léveillé F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 2008 22 : 4258 4271.
113. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007 8 : 413 426.
114. Zhang SJ, Steijaert MN, Lau D, Schütz G, Delucinge-Vivier C, Descombes P, Bading H. Decoding NMDA receptor signaling: Identification of genomic programs specifying neuronal survival and death. Neuron 2007 53 : 549 562.
115. van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 2009 5 : 237 247.
116. Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull 2005 64 : 519 524.
117. Jones R, Sheehan B, Phillips P, et al DOMINO-AD team. DOMINO-AD protocol: Donepezil and memantine in moderate to severe Alzheimer's disease - A multicentre RCT. Trials 2009 10 : 57 : 1 11.